An updated guideline and panel recommends treatment with sacituzumab govitecan for patients with HR-positive/HER2-negative metastatic breast cancer who are refractory to endocrine therapy.
An updated guideline from the American Society of Clinical Oncology (ASCO) recommends that patients with hormone receptorpositive, HER2-negative metastatic breast cancer who are refractory to endocrine therapy would benefit from treatment with sacituzumab govitecan (Trodelvy).1
The guideline, originally completed in 2021,2 was updated to reflect findings from the phase 3 TROPiCS-02 trial (NCT03901339). The guideline update was well timed; a month after it was published, the FDA approved the use of sacituzumab govitecan for the treatment of adult patients with unresectable, locally advanced, or metastatic hormone receptor–positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+/in situ hybridization negative) breast cancer who have received endocrine-based therapy and at least 2 systemic regimens in the metastatic setting.3
The original guideline recommended that patients with hormone receptor–positive, HER2-negative metastatic breast cancer should be considered for single-agent chemotherapy, or a chemotherapy combination regimen in the case of highly symptomatic disease.
TROPiCS-02 was a global, randomized phase 3 study comparing the use of sacituzumab govitecan (n = 272), a Trop-2 antibody-drug conjugate, with physician’s choice of chemotherapy (n = 271) for patients with endocrine-resistant and unresectable, locally advanced, or metastatic hormone receptor–positive, HER2-negative breast cancer who were pretreated with chemotherapy. In the control arm, chemotherapy consisted of eribulin, capecitabine, gemcitabine, or vinorelbine.
At a median follow-up of 10.2 months, the median progression-free survival (PFS) by blinded independent central review was 5.5 months (95% CI, 4.2-7.0) and 4.0 months (95% CI, 3.1-4.4) with chemotherapy, meeting the primary end point of the trial (HR, 0.73; 95% CI, 0.60-0.88; P = .001).4
PFS rates were 46% with sacituzumab govitecan and 30% with chemotherapy at 6 months, and 21% vs 7%, respectively, at 12 months.
Objective responses were observed in 21% of patients in the sacituzumab govitecan arm and in 14% of the chemotherapy arm, with 2 patients in the investigational arm achieving a complete response. The median duration of response was 7.4 months (95% CI, 6.5-8.6) with sacituzumab govitecan and 5.6 months (95% CI, 3.8-7.9) with chemotherapy.
Overall survival (OS) results presented at the European Society for Medical Oncology Congress 2022 showed further benefit for the antibody-drug conjugate, with a median OS of 14.4 months with sacituzumab govitecan compared with 11.2 months with physician’s choice of chemotherapy (HR, 0.79; 95% CI, 0.65-0.96; P = .02).5
The agent was also considered to have a manageable safety profile. The most important and common treatment-related adverse events of grade 3 or higher with sacituzumab govitecan compared with chemotherapy were neutropenia (51% vs 38%) and diarrhea (9% vs 1%).
Following the release of the TROPiCS-02 data, the ASCO guideline’s expert panel, led by Beverly Moy, MD, MPH, clinical director of the Breast Oncology Program at Massachusetts General Hospital, conducted another search of literature to see whether any other randomized, controlled phase 3 trials could affect the patient population.
Looking at the study data, the panel recommended use of sacituzumab govitecan for this patient population.
Overcoming Barriers in Cancer Clinical Trials: A Path Forward for Better Patient Care
April 29th 2024Clinical trials play a pivotal role in developing effective therapies, yet their integration is challenged by issues such as insufficient reimbursement structures, misaligned incentives, physician burnout, and a complex regulatory environment.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More